Table 7.

CG in vivo anti-herpesvirus activities. (PFU, plaque-forming unit; LD₅₀, half-maximal lethal dose; MCMV, murine cytomegalovirus; FHV-1, feline herpesvirus-1; CPE, cytopathic effect; FDI, fast-dissolving insert; qPCR, quantitative polymerase chain reaction).

CG Type	Efficacy Model	Dose	Antiviral Assay	Administration	Effects	Ref
ι-CG type V	ICR mice infected with MCMV	0.5 mg	PFU	Intraperitoneal	Decreased mortality and titer and increased PFU/LD50	[63]
ι-CG type V	ICR mice infected with MCMV	0.5 mg	PFU	Intraperitoneal	Inhibition of viral spread from the peritoneal cavity to the plasma	[62]
λ/κ/ι-CG	BALB/c mice infected with HSV-2	0.05–1%	PFU in vaginal secretion	Vaginal	Inhibition of infection	[89]
κ-CG	C57B1/6 mice infected with HSV-2	0.1–100 mg/mL	Shedding of virus, visible lesions, and CPE	Vaginal	Inhibition of infection	[81]
CG-based nonoxynol-9	BALB/c mice infected with HSV-2	20 ul of 3%	Symptom of infection	Vaginal	Inhibition of infection	[90]
λ-CG type IV (1T1), ι-CG type V	Swiss Webster mice infected with HSV-2	10 mg/mL	Sign of disease	Vaginal	Inhibition of infection	[82]
λ-CG	BALB/c mice infected with HSV-2	2 and 3%	Survival	Vaginal	100% survival	[87]
λ-CG 1T1	BALB/c mice infected with HSV-2	10 mg/mL	PFU and survival	Vaginal	90% survival and no virus shedding	[84]
κι/ν-CG C2	BALB/c mice infected with HSV-2	8 mg/mL	PFU and survival	Vaginal	70% survival	[40]
λ-CG type IV	FHV-1 induced conjunctivitis in cats	250 µg/mL	PFU	Topical	Reduction of virus titers but no alteration in the clinical course	[88]
λ/κ-CG + ZA	BALB/c mice infected with HSV-2	20 µL of 3%	Survival	Vaginal and rectal	Inhibition of infection	[85]
λ/κ-CG + ZA	BALB/c mice infected with HSV-2	20 µL of 3%	Survival	Vaginal and rectal	Inhibition of infection	[8]
CG + griffithsin	BALB/c mice infected with HSV-2	50 µL of griffithsin solution (19.1 mg/mL)	Infection rate	Vaginal	Inhibition of infection	[86]
CG + MIV-150 + ZA	BALB/c mice infected with HSV-2	10 µL of stock	qPCR	Vaginal	Inhibition of infection	[7]
CG + griffithsin	BALB/c mice infected with HSV-2	10 µL of 0.1% stock	qPCR	Vaginal	Inhibition of infection	[80]